This web site was copied prior to January 20, 2005. It is now a Federal record managed by the National Archives and Records Administration. External links, forms, and search boxes may not function within this collection.
Learn more.
[
hide]

Foreword
Genomics and Population Health, 2003: Year at a Glance
Genomics Lingo…..What Do the Terms Mean?
List of Authors
I. Population Health Research
- Chapter 1
National Health and Nutrition Examination Survey (NHANES) III DNA Bank:
Gene Variants Important to Public Health
NHANES III DNA Bank • Collaborative CDC-Wide Proposal • Selecting Genetic Variants Important to Public Health • Potential Value for Public Health • Two Other CDC Projects Using NHANES III DNA Samples
- Chapter 2
Genomics and Acute Public Health Investigations
What is an Acute Public Health Investigation (APHI)? • Incorporating Human Genomics into APHIs • APHI Working Group
II. Building the Evidence Base
- Chapter 3
Asthma Genomics: Implications for Public Health
What Causes Asthma? • Public Health Implications of Asthma Genomics Research
• Pharmacogenomics and Predictive Testing • Public Health Actions—Asthma Genomics Research
- Chapter 4
Public Health Assessment of BRCA1 and BRCA2 Testing for Breast and Ovarian Cancer
Breast and Ovarian Cancer: An Important Public Health Problem • Genetic Tests for Breast and Ovarian Cancer Susceptibility • A Public Health Perspective • The Role of Family History in BRCA1 and BRCA2 Testing • The Role of Genetic Counseling in BRCA1 and BRCA2 Testing • Surveillance and Risk-Reducing Strategies for Breast and Ovarian Cancer
• Evaluation of BRCA1 and BRCA2 Testing in Practice • Effectiveness of BRCA1 and BRCA2 Testing for Prevention
- Chapter 5
Newborn Screening for MCAD Deficiency
What is MCADD? • Why Test Newborns for MCADD? • Tandem Mass Spectrometry Screening Test • Adding MCADD Screening to Existing Newborn Screening Programs • Is Universal Screening for MCADD Justified? • Cost-Effectiveness of Newborn MCADD Screening
• Challenges for Implementing MCADD Screening
- Chapter 6
The Family History Public Health Initiative
Family History is Valuable for Prevention • Disease Risk Due to Gene-Environment Interactions • Role of Genetic Testing • Family History and the Family Tree • The CDC Family History Initiative • Selecting Diseases to Include in a Family History Tool • Prototype Family History Tool • Data Collection • Classification • Intervention • Evaluation Studies
- Chapter 7
Genetic Testing and the Prevention of Coronary Heart Disease: A Case Study
Will a Genomic Profile Help Prevent Coronary Heart Disease (CHD)? • Is Genomic Profiling for CHD Ready for Prime Time? • Medical Family History as Genomic Profiling • Family History is Still the Best Genomic Tool • Guidelines for CHD Prevention
- Chapter 8
Genomics and Public Health: Ethical, Legal, and Social Issues
Ethical, Legal, and Social Issues (ELSI) • Public Health Ethical Legal, and Social Issues (PHELSI) • Is PHELSI Different from ELSI? • Public Health Ethics • Ethical Issues in Public Health Genomics • Legal Issues in Public Health Genomics • Social Issues in Public Health Genomics • Engagement and Education to Address PHELSI • A Genetic Agenda for Public Health
III. Genomics in Practice
- Chapter 9
Carrier Testing for Cystic Fibrosis: Transition from Research to Clinical Practice
About Cystic Fibrosis • CFTR: The CF Gene • Cystic Fibrosis Carrier Testing • History of CF Testing in the United States • CF Testing in the United States: Transition from Research to Clinical Practice • Evaluation of Prenatal CF Screening • 2003: Learning from Implementation and Practice • Public Health Importance of Lessons Learned
- Chapter 10
Ensuring the Quality of Genetic Testing in the United States
Why is the Quality of Genetic Testing Important to Public Health? • Genetic Testing Issues • Who Considers These Issues in the United States? • What Oversight Currently Exists for Genetic Testing? • “Home Brew” Genetic Tests and the FDA • How Do States Regulate Genetic Testing? • What Private Sector Organizations Are Concerned with Genetic Testing? • What is Needed to Ensure the Safety of Genetic Testing? • How is CDC Addressing These Needs?
- Chapter 11
Hemochromatosis: Information and Resources for Health Care Providers
What is Hemochromatosis? • Why is Hemochromatosis a Public Health Problem? • Is Population Screening Recommended for Hemochromatosis? • CDC’S Online Training on Hemochromatosis for Health Care Providers
- Chapter 12
Genomics Training for Public Health Practice: The Michigan Experience
Why Does the Public Health Workforce Need Genomics Training? • What Has Been Done to Develop Genomics Training? • Simple Training Strategies and Available Courses • Strategy 1: Building a Foundation—Know Your Audience • Strategy 2: Raising Awareness and Stimulating Interest • Strategy 3: Increasing Knowledge • Strategy 4: Strengthening Skills
• Strategy 5: Using Evaluation to Improve Training • Lessons Learned
- Chapter 13
Genomics Tools for Public Health
What are Genomic Tools? • Genomic Tools in Practice and the Genomics Toolkit • Genomic Tools We Need, But Don’t Currently Have • How Will New Tools Be Developed? • Thinking Genomically—the Vision for the Future
- Chapter 14
State Capacity Grants for Integrating Genomics into Chronic Disease Prevention Programs
Michigan, Minnesota, Oregon and Utah Genomics and Chronic Disease Prevention Programs • Michigan • Minnesota • Oregon • Utah • Next Steps
- Chapter 15
Internet Resources for Genomics and Disease Prevention
CDC Office of Genomics and Disease Prevention (OGDP) • Human Genome Project
• Genomic Research • Genetic Testing • Family History • Genes and Diseases • Cancer
• Birth Defects • Newborn Screening • Public Health Ethical, Legal, and Social Issues (PHELSI) • Policy • Public Health Resources • Educational Resources
|
|